ATRN:

*Data is delayed | USD
after hours iconAfter Hours: Last |
quote price arrow down ()
Close
quote price arrow down ()
52 week range
-
Loading...
  • Open-
  • Day High-
  • Day Low-
  • Prev Close-
  • 52 Week High-
  • 52 Week High Date-
  • 52 Week Low-
  • 52 Week Low Date-

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open-
  • Day High-
  • Day Low-
  • Prev Close-
  • 52 Week High-
  • 52 Week High Date-
  • 52 Week Low-
  • 52 Week Low Date-
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On undefined

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Protagenic Therapeutics, Inc. is a biopharmaceutical company. The Company specializes in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-residue peptide synthetic TCAP-1. In addition, it has a portfolio of...
Garo Armen Ph.D.
Executive Chairman of the Board
Andrew Slee Ph.D.
Chief Operating Officer
Alexander Arrow M.D.
Chief Financial Officer
Address
149 FIFTH AVENUE, SUITE 500
New York, NY
10010
United States